Related Experiment Video
Updated: Jun 26, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience
1Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea.
Current Oncology (Toronto, Ont.)
|June 25, 2026
Summary
Radiotherapy effectively controls adrenal metastases from hepatocellular carcinoma (HCC), showing high response rates and local control with minimal toxicity. This treatment offers a valuable option for managing these challenging tumors.
Area of Science:
- Oncology
- Radiation Oncology
- Hepatocellular Carcinoma Research
Background:
- Adrenal metastases from hepatocellular carcinoma (HCC) present a clinical challenge.
- Evaluating the efficacy of radiotherapy for these metastases is crucial.
Purpose of the Study:
- To assess tumor response, local control (LC), survival, and toxicity of radiotherapy for adrenal metastases in HCC patients.
- To explore the relationship between biologically effective dose (BED10) and local recurrence.
Main Methods:
- Retrospective, bi-institutional study of 20 patients treated with various radiotherapy techniques (2005-2025).
- Tumor response assessed by RECIST v1.1; LC, OS, and PFS estimated by Kaplan-Meier.
- Fisher's exact test used to analyze BED10 and local recurrence association.
Main Results:
- Objective response rate was 55.0%, with a 95.0% disease control rate.
- 6- and 12-month LC rates were 94.4% and 87.2%, respectively; 15.0% experienced local recurrence.
- No local recurrence observed with BED10 ≥ 75 Gy (exploratory finding). Median OS was 13.4 months, median PFS was 6.3 months. No grade ≥3 toxicity.
Conclusions:
- Radiotherapy demonstrates favorable local control and acceptable toxicity for adrenal HCC metastases.
- Supports radiotherapy as an effective local treatment for adrenal metastases in HCC.
